Cymbalta
(Duloxetine Hydrochloride)ApprovedSmall molecule
Jazz PharmaceuticalsCymbalta is a small molecule that works as a Norepinephrine Transporter Inhibitor; Serotonin Transporter Inhibitor.[2] It is being used across 8 indications, with its most advanced program in Approved.[1]
Cymbalta is one of 241 small molecule programs targeting Peripheral Neuropathy. It is currently in Approved.
8
Indications
42
Total Trials
1
Active Trials
240
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
317 competitors in COVID-19
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Calciferol
Jazz PharmaceuticalsPreclinical
Activella
Eli LillyPreclinical
Angiomax
BBaxter Healthcare Corporation
Preclinical
Benadryl
PParkedale
Preclinical
Nitrostat
VViatris Specialty LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Major Depressive Disorder6 trials
Depression5 trials
Neuropathic Pain3 trials
Generalized Anxiety Disorder3 trials
19 more indications
Stress urinary incontinence2 trials
Diabetic Neuropathy2 trials
Depressive Disorder2 trials
Fibromyalgia2 trials
Shugan Dingtong Decoction in the Treatment of Fibromyalgia
Completed·—·Phase 1·NCT05508516·72 enrolled
Trial1 trial
Efficacy1 trial
Short-term Efficacy of Antidepressant in Patients Underwent TKA
Unknown status·—·Phase 1/2·NCT03110172·32 enrolled
Efficacy and Safety1 trial
Fed1 trial
Randomized1 trial
Severe Depression1 trial
Clinical Trial1 trial
Breast Cancer1 trial
Parkinson's Disease1 trial
Post-Traumatic Stress Disorder1 trial
Open-Label Duloxetine Monotherapy in the Treatment of Posttraumatic Stress Disorder
Unknown status·—·Phase 3·NCT00583193·20 enrolled
Regulatory
FDA Approval Timeline[4]
Aug 3, 2004
CYMBALTA
NDA NDA021427
Jul 19, 2019
DRIZALMA SPRINKLE
NDA NDA212516
Feb 27, 2026
DULOXETINE HYDROCHLORIDE
NDA NDA219131
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Duloxetine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Norepinephrine Transporter Inhibitor; Serotonin Transporter Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
Patent Landscape[5]
Patent Cliff
Jan 13, 2046
Earliest patent expiration — generic entry possible after this date
Patent #Expires
12721817Jan 13, 2046